Australia markets closed

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.9100-0.0474 (-4.95%)
At close: 03:59PM EST
0.9302 +0.02 (+2.22%)
After hours: 04:37PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.9574
Open0.9800
Bid0.0000 x 800
Ask0.0000 x 1100
Day's range0.9100 - 0.9800
52-week range0.9000 - 9.4500
Volume27,285
Avg. volume67,714
Market cap7.425M
Beta (5Y monthly)0.31
PE ratio (TTM)N/A
EPS (TTM)-0.3470
Earnings date09 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.00
  • GlobeNewswire

    Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

    REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2022. Third Quarter 2022 and Recent Corporate Highlights Initiated the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Chol

  • Zacks

    Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why

    Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.

  • GlobeNewswire

    Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

    REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). “Initiation of the randomized withdrawal per